Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cerevel Therapeutics Holdings, Inc. CERE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
22/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$33.50
-25.5%

Balance sheet is a point-in-time snapshot. TTM shows the most recent available quarter.

Metric Latest Quarter (2024-03)
Total Assets $1.13B
Total Liabilities $562.89M
Total Debt $368.3M
Cash & Investments $846.29M
Total Stockholders Equity $564.46M

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$152.54
+3.76%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 NUVL
NUVL
Nuvalent, Inc.
$104.75
-0.26%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
-0.01%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 TVTX
TVTX
Travere Therapeutics, Inc.
$40.95
-2.80%
 SWTX
SWTX
SpringWorks Therapeutics, Inc.
$46.99
+0.02%
 GPCR
GPCR
Structure Therapeutics Inc.
$54.25
+1.94%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message